Apimeds Pharmaceuticals US, Inc. (APUS) — Long-term Investment Intensity
Apimeds Pharmaceuticals US, Inc. (APUS) has a Long-term Investment Intensity of 90.5% as of March 2026. Long-term investments of $127.82 Million represent 90.5% of total assets of $141.22 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Read how much debt does Apimeds Pharmaceuticals US, Inc. carry for a breakdown of total debt and financial obligations.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Apimeds Pharmaceuticals US, Inc. Long-term Investment Intensity (2025–2025)
This chart shows how Apimeds Pharmaceuticals US, Inc.'s Long-term Investment Intensity has evolved across 1 annual periods from 2025 to 2025. As of March 2026, the intensity stands at 90.5%, reflecting long-term investments of $127.82 Million against total assets of $141.22 Million USD. Check Apimeds Pharmaceuticals US, Inc. (APUS) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Annual Long-term Investment Intensity for Apimeds Pharmaceuticals US, Inc. (2025–2025)
The table below presents the year-by-year Long-term Investment Intensity for Apimeds Pharmaceuticals US, Inc. from 2025 to 2025, covering 1 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of Apimeds Pharmaceuticals US, Inc..
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2025 | 91.3% | $149.89 Million | $164.18 Million | — |